Добірка наукової літератури з теми "NSCLCs"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "NSCLCs".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "NSCLCs"
Awad, Mark M., Geoffrey R. Oxnard, David M. Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C. Heng, et al. "MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression." Journal of Clinical Oncology 34, no. 7 (March 1, 2016): 721–30. http://dx.doi.org/10.1200/jco.2015.63.4600.
Повний текст джерелаMaitra, Radhashree, Parth Malik, and Tapan Kumar Mukherjee. "Targeting Estrogens and Various Estrogen-Related Receptors against Non-Small Cell Lung Cancers: A Perspective." Cancers 14, no. 1 (December 24, 2021): 80. http://dx.doi.org/10.3390/cancers14010080.
Повний текст джерелаFarago, Anna F., Martin S. Taylor, Robert C. Doebele, Viola W. Zhu, Shivaani Kummar, Alexander I. Spira, Theresa A. Boyle, et al. "Clinicopathologic Features of Non–Small-Cell Lung Cancer Harboring an NTRK Gene Fusion." JCO Precision Oncology, no. 2 (November 2018): 1–12. http://dx.doi.org/10.1200/po.18.00037.
Повний текст джерелаNowinska, Jablonska, Pawelczyk, Piotrowska, Partynska, Gomulkiewicz, Ciesielska, et al. "Expression of Irisin/FNDC5 in Cancer Cells and Stromal Fibroblasts of Non-small Cell Lung Cancer." Cancers 11, no. 10 (October 11, 2019): 1538. http://dx.doi.org/10.3390/cancers11101538.
Повний текст джерелаYan, Dan, H. Shelton Earp, Deborah DeRyckere, and Douglas K. Graham. "Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer." Cancers 13, no. 22 (November 11, 2021): 5639. http://dx.doi.org/10.3390/cancers13225639.
Повний текст джерелаLandre, Thierry, Gregoire Justeau, Jean-baptiste Assié, Kader Chouahnia, Chérifa Taleb, Christos Chouaid, and Boris Duchemann. "Anti PD-(L)1 in KRAS mutant advanced nsclcs: A meta-analysis of randomized controlled trials." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 9025. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.9025.
Повний текст джерелаLiu, Jia-Chun, Suresh Narva, Kang Zhou, and Wen Zhang. "A Review on the Antitumor Activity of Various Nitrogenous-based Heterocyclic Compounds as NSCLC Inhibitors." Mini-Reviews in Medicinal Chemistry 19, no. 18 (November 29, 2019): 1517–30. http://dx.doi.org/10.2174/1389557519666190312152358.
Повний текст джерелаWang, Hsiang-Sheng, Chien-Ying Liu, Sheng-Chi Hsu, Shih-Chiang Huang, Tsai-Hsien Hung, Kwai-Fong Ng, and Tse-Ching Chen. "A Single-Institute Experience with C-ros Oncogene 1 Translocation in Non-Small Cell Lung Cancers in Taiwan." International Journal of Molecular Sciences 23, no. 10 (May 21, 2022): 5789. http://dx.doi.org/10.3390/ijms23105789.
Повний текст джерелаGasparini, Pierluigi, Luciano Cascione, Lorenza Landi, Stefania Carasi, Francesca Lovat, Carmelo Tibaldi, Greta Alì, et al. "microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers." Proceedings of the National Academy of Sciences 112, no. 48 (November 16, 2015): 14924–29. http://dx.doi.org/10.1073/pnas.1520329112.
Повний текст джерелаSerresi, Michela, Bjorn Siteur, Danielle Hulsman, Carlos Company, Matthias J. Schmitt, Cor Lieftink, Ben Morris, et al. "Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities." Journal of Experimental Medicine 215, no. 12 (November 28, 2018): 3115–35. http://dx.doi.org/10.1084/jem.20180801.
Повний текст джерелаДисертації з теми "NSCLCs"
Chater, Emily. "Novel therapeutic targets in NSCLC resistance to Erlotinib." Thesis, Imperial College London, 2017. http://hdl.handle.net/10044/1/50699.
Повний текст джерелаHolgersson, Georg. "Prognostic Factors in Non-Small Cell Lung Cancer (NSCLC)." Doctoral thesis, Uppsala universitet, Experimentell och klinisk onkologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-327925.
Повний текст джерелаStamatkin, Christopher W. "PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) AS A THERAPEUTIC TARGET IN NSCLC." UKnowledge, 2014. http://uknowledge.uky.edu/pharmacy_etds/58.
Повний текст джерелаChatterjee, Saradiya. "Role of TLR7 in non-small cell lung carcinona (NSCLC)." Paris 6, 2013. http://www.theses.fr/2013PA066063.
Повний текст джерелаLung cancer accounts for over 1 million deaths per year with a 5-year survival of 8-12%. Stimulation of TLRs by the natural ligands like the PAMPs and DAMPs results in a proinflammatory signaling cascade. We have shown that stimulation of lung cancer cell lines with TLR7 agonist lead to tumor cell survival and chemoresistance in vitro. We studied the effect of TLR7 agonists on A549 and LL/2 cells injected in NOD/SCID and C57BL/6 mice either treated or not with cisplatin. Loxoribine has a pro-tumoral effect on A549 cells and induces chemoresistance in NOD/SCID mice. Blockade of TLR7 with IRS661 reversed the pro-tumoral effect of TLR7 agonist on A549 cells. CL264 was also found to have a pro-tumoral effect on LL/2 cells and induced chemoresistance in NOD/SCID mice. On the other hand CL264 at lower concentration induces an anti-tumoral effect on LL/2 cells while at a higher concentration demonstrated a pro-tumoral effect in C57BL/6 mice. We also demonstrated an overall bad prognostic value for higher expression of TLR7 by tumoral cells among NSCLC patients treated and not treated with neoadjuvant chemotherapy. These results suggest a pro- tumoral role and induction of chemoresistance by TLR7 in NSCLC patients. Use of TLR7 agonist as therapeutic option is recommended based on the TLR7 expression level for individual NSCLC patients. TLR7 antagonist holds promise for treatment of NSCLC in future
Recondo, Gonzalo. "Resistance Mechanisms to ALK Tyrosine Kinase Inhibitors (TKIs) in NSCLC." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS248/document.
Повний текст джерелаThe molecular study and classification of lung adenocarcinomas has led to the development of selective targeted therapies aiming to improve disease control and survival in patients. The anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor from the insulin tyrosine kinase receptor family, with a physiologic role in neural development. Gene rearrangements involving the ALK kinase domain occur in ~3-6% of patients with lung adenocarcinoma. The fusion protein dimerizes leading to transactivation of the ALK kinase domain in a ligand-independent and constitutive manner. Lorlatinib is a third generation ALK inhibitor with high potency and selectivity for this kinase in vitro and in vivo, and elevated penetrance in the central nervous system. Lorlatinib can overcome resistance mediated by over 16 secondary kinase domain mutations occurring in 13 residues upon progression to first - and second - generation ALK TKI. In addition, treatment with lorlatinib is effective for patients who have been previously treated with a first and a second generation or a second generation ALK TKI upfront and is currently approved for this indication. The full spectrum of biological mechanisms driving lorlatinib resistance in patients remains to be elucidated. It has been recently reported that the sequential acquisition of two or more mutations in the kinase domain, also referred as compound mutations, is responsible for disease progression in about 35% of patients treated with lorlatinib, mainly by impairing its binding to the ALK kinase domain. However, the effect of these compound mutations on the sensitivity to the repertoire of ALK inhibitors can vary, and other resistance mechanisms occurring in most patients are unknown. My PhD thesis aimed at exploring resistance to lorlatinib in patients with ALK-rearranged lung cancer through spatial and temporal tumor biopsies and development of patient-derived models. Within the institutional MATCH-R study (NCT02517892), we performed high-throughput whole exome, RNA and targeted next-generation sequencing, together with plasma sequencing to identify putative genomic and bypass mechanisms of resistance. We developed patient-derived cell lines and characterized novel mechanisms of resistance and personalized treatment strategies in vitro and in vivo. We characterized three mechanisms of resistance in four patients with paired biopsies. We studied the induction of epithelial-mesenchymal transition (EMT) by SRC activation in a patient-derived cell line exposed to lorlatinib. Mesenchymal cells were sensitive to combined SRC and ALK co-inhibition, showing that even in the presence of an aggressive and challenging phenotype, combination strategies can overcome ALK resistance. We identified two novel ALK kinase domain compound mutations, F1174L/G1202R, C1156Y/G1269A, occurring in two patients treated with lorlatinib. We developed Ba/F3 cell models harboring single and compound mutations to study the differential effect of these mutations on lorlatinib resistance. Finally, we characterized a novel mechanism of resistance caused by NF2 loss of function at the time of lorlatinib progression through the development of patients derived PDX and cell lines, and in vitro validation of NF2 knock-out with CRISPR/CAS9 gene editing. Downstream activation of mTOR was found to drive lorlatinib resistance by NF2 loss of function and was overcome by providing treatment with mTOR inhibitors.This study shows that mechanisms of resistance to lorlatinib are more diverse and complex than anticipated. Our findings also emphasize how longitudinal studies of tumor dynamics allow deciphering TKI resistance and identifying reversing strategies
Baghai, Tabassom. "ATF3 as a Key Regulator of Cisplatin Cytotoxicity: Combining ATF3 Inducing Agents Enhances Cisplatin Activity in NSCLC." Thesis, Université d'Ottawa / University of Ottawa, 2018. http://hdl.handle.net/10393/37963.
Повний текст джерелаSouza, Cristiano de Pádua. "Perfil de expressão de microRNAs e seus alvos moleculares em carcinoma pulmonar." Botucatu, 2016. http://hdl.handle.net/11449/140150.
Повний текст джерелаResumo: Introdução: O câncer de pulmão é a principal causa de morte por câncer no mundo. Apesar dos avanços nas estratégias de diagnóstico e o desenvolvimento de novas terapias com alvos moleculares, pouco progresso tem sido observado quanto ao aumento de sobrevida dos pacientes. Portanto, a identificação de novos biomarcadores ainda é necessária para o desenvolvimento de novas terapêuticas para carcinomas pulmonares. Nesse contexto, os microRNAs (miRNAs) são moléculas promissoras, pois constituem uma classe de RNAs não-codantes reguladores da expressão gênica os quais têm sido evidenciados como biomarcadores diagnósticos, prognósticos e preditivos no câncer. Materiais e Métodos: Amostras de tecido pulmonar tumoral e normal de 38 pacientes com carcinoma de pulmão de células não pequenas (da sigla em inglês NSCLC), dos subtipos histológicos adenocarcinoma e carcinoma de células escamosas, foram avaliadas para a expressão global de miRNAs utilizando a plataforma TaqMan® Array Human MicroRNA card A v3.0 (Life Technologies). Os miRNAs com alterações na expressão (FC≥2,0) e p<0,05 foram considerados estatisticamente significativos. Os dados de expressão foram associados com a sobrevida global. Análises de bioinformática permitiram identificar genes-alvo regulados pelos miRNAs desregulados. A relação entre sobrevida global e a identificação de uma assinatura de expressão de miRNAs foi avaliada com objetivo de integrar nossos achados utilizando bancos de dados públicos. Resultados: Os resul... (Resumo completo, clicar acesso eletrônico abaixo)
Doutor
Campbell, Thomas. "The role of voltage-gated sodium channels in non-small cell lung cancer." Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/the-role-of-voltagegated-sodium-channels-in-nonsmall-cell-lung-cancer(a65f4c5e-b217-483b-91d3-bb669965eb03).html.
Повний текст джерелаBen, hamed Ibtissem. "Réponses cellulaires rapides de l’halophyte Cakile maritima au choc salin : analyse de leur implication dans la mort cellulaire programmée et l’adaptation." Thesis, Université Paris-Saclay (ComUE), 2016. http://www.theses.fr/2016SACLS444.
Повний текст джерелаAbstractThis work aimed at understanding the specificity of cellular responses of the obligate halophyte Cakile maritima to salt shock and regulation of early events involved in programmed cell death and survival under salinity conditions. In a first step, we have shown that this plant is tolerant upon both repetitive salt shocks and gradual salt application. However, we have observed a cell death zones on older leaves subjected to a severe shock saline (400 mM NaCl). To better understand the cascade of events involved in the cell death process, we continued our experiments on suspension culture of C. maritima, which we have optimized ourselves the conditions for establishment and suspension culture of Arabidopsis thaliana (glycophyte model). In both species, salinity induced programmed cell death that depends on the duration and the intensity of the applied salt treatment. Also, the same cellular events, including depolarization of the plasma membrane due to the Na+ influx by NSCCs, mitochondrial dysfunction, production of superoxide anions and activation of caspase-like proteins, occurs early in response to salt stress. C. maritima tolerance to salt stress is potentially due to a strong accumulation of ascorbate that would allow this halophyte to better reduce damage generated by oxidative stress. C. maritima is also distinguished by a better ability to control the cytoplasmic accumulation of Na+, leading to the survival of its cells under salinity conditions. This study on cell death induced by NaCl in cell culture of C. maritima also allowed us to identify two types of behavior in this population of cells in culture: one related to a sustained depolarization in response to NaCl probably leading to death of these cells, the other linked to a transient depolarization indicating that the Na+ influx through the NSCC was probably regulated allowing cells exhibiting this behavior to survive by avoiding excessive accumulation of Na+ in the cytosol. In the last part of this work, we have demonstrated the ability of C. maritima to exclude Na+ via the SOS system. This result suggests the existence of a second signaling pathway induced in parallel to that leading to cell death. This pathway, involving a rapid production of singlet oxygen, could allow a Ca2+ influx in the cytoplasm that acts as an elicitor for activation of SOS3 protein and SOS2-SOS1 cascade and H+- ATPases of the plasma membrane allowing Na+ efflux via SOS1 out of cells
Schaal, Courtney. "Regulation of nAChRs and Stemness by Nicotine and E-cigarettes in NSCLC." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6582.
Повний текст джерелаКниги з теми "NSCLCs"
Cappuzzo, Federico. Guide to Targeted Therapies: EGFR mutations in NSCLC. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-03059-3.
Повний текст джерелаNational Strength & Conditioning Association (U.S.), ed. NSCA's essentials of personal training. 2nd ed. Champaign, IL: Human Kinetics, 2012.
Знайти повний текст джерела1961-, Hoffman Jay, ed. NSCA's guide to program design. Champaign, IL: Human Kinetics, 2012.
Знайти повний текст джерела1967-, Miller Todd, ed. NSCA's guide to tests and assessments. Champaign, IL: Human Kinetics, 2012.
Знайти повний текст джерелаCampbell, Bill. NSCA's guide to sport and exercise nutrition. Edited by National Strength & Conditioning Association (U.S.). Champaign, IL: Human Kinetics, 2011.
Знайти повний текст джерела1975-, Campbell Bill, and Spano Marie 1972-, eds. NSCA's guide to sport and exercise nutrition. Champaign, IL: Human Kinetics, 2011.
Знайти повний текст джерелаKim, Ho-jung. array-CGH rŭl iyong han piso sepʻo pʻyeam ŭi chogi chaebal pʻyojija mit chindan mohyŏng kaebal =: Development of early-recurrence detection marker and diagnostic model using array-CGH in NSCLC. [Seoul]: Pogŏn Pokchibu, 2007.
Знайти повний текст джерелаHaffen, Bernard. Secrets exposed: Discrimination still exist in the nscs, in the good ole boy racing series, the proof and the truth shall set you free! New York: iUniverse Inc, 2009.
Знайти повний текст джерелаSouthern African People's Solidarity Network, ed. The 2008 [i.e 2009] SADC Peoples' Summit report: Reclaiming SADC for peoples' solidarity development cooperation : taking ownership of our resources for people solidarity : converned by the Southern Africa Peoples' Solidarity Network (SAPSN) in Kinshasa, Democratic Republc of Congo : hosted by Forum of Congolese Organisations in South Africa (FOSA) and Nouvelle Societe Civile Congolaise (NSCC) : dates 5-6 September 2009. Harare, Zimbabwe: Southern African Peoples' Solidarity Network, 2009.
Знайти повний текст джерелаCappuzzo, Federico. Guide to Targeted Therapies : EGFR mutations in NSCLC: EGFR mutations in NSCLC. Adis, 2014.
Знайти повний текст джерелаЧастини книг з теми "NSCLCs"
Shih, Helen. "BRAF in NSCLC." In Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners, 39–49. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16550-5_5.
Повний текст джерелаDu, Lingling, Saiama N. Waqar, and Daniel Morgensztern. "Multimodality Therapy for NSCLC." In Cancer Treatment and Research, 151–63. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-40389-2_7.
Повний текст джерелаCappuzzo, Federico. "Therapy options for advanced NSCLC." In Guide to Targeted Therapies: Treatment Resistance in Lung Cancer, 5–25. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-20741-4_2.
Повний текст джерелаDoubre, H., C. Le Pechoux, and T. Le Chevalier. "Adjuvant Treatments in Resectable NSCLC." In Malignant Tumors of the Lung, 215–25. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18698-1_19.
Повний текст джерелаRamírez, J. L., M. F. Salazar, J. Gupta, J. M. Sánchez, M. Taron, M. Sänchez-Ronco, Vicente Alberola, and R. de las Peñas. "Methylation Patterns and Chemosensitivity in NSCLC." In New trends in cancer for the 21st century, 195–209. Dordrecht: Springer Netherlands, 2006. http://dx.doi.org/10.1007/978-1-4020-5133-3_17.
Повний текст джерелаBlackhall, Fiona H. "Strategies in ALK Rearranged NSCLC Patients." In New Therapeutic Strategies in Lung Cancers, 147–56. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06062-0_10.
Повний текст джерелаLouie, Brian E., and Eric Vallières. "Minimally Invasive Surgery for Early NSCLC." In New Therapeutic Strategies in Lung Cancers, 27–32. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06062-0_3.
Повний текст джерелаPisters, Katherine. "Adjuvant and Neoadjuvant Therapy of NSCLC." In Lung Cancer, 139–59. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_6.
Повний текст джерелаTsao, Anne S., and Jack A. Roth. "Novel and Emerging Agents in NSCLC." In Lung Cancer, 464–78. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch30.
Повний текст джерелаDas, Millie, and Heather Wakelee. "Anti-Angiogenic Agents in Metastatic NSCLC." In Lung Cancer, 527–40. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118468791.ch34.
Повний текст джерелаТези доповідей конференцій з теми "NSCLCs"
Altenberger, Corinna, Gerwin Heller, Bianca Schmid, Barbara Ziegler, Leonhard Müllauer, György Lang, Adelheid End-Pfützenreuter, et al. "Abstract 397: Transcriptional regulation of SPAG6 by DNA methylation in NSCLCs." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-397.
Повний текст джерелаBritt, Rebecca R., and John D. Minna. "Abstract 3780: Autophagy targeting therapies in NSCLC: Autophagy induction vs. inhibition in combination with erlotinib shows Torin1 can sensitize NSCLCs with KRAS mutations to Erlotinib." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3780.
Повний текст джерелаChalla, Sridevi, Jian-Ping Guo, Cheng-xiong Xu, Yajuan Li, Donghwa Kim, Douglas Cress, Eric Haura, Domenico Coppola, and Jin Cheng. "Abstract 1890: IKBKE is a substrate of EGFR and a therapeutic target in NSCLCs with activating mutations of EGFR." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1890.
Повний текст джерелаTagal, Vural, Shuguang Wei, Wei Zhang, Rolf A. Brekken, Bruce A. Posner, Adi F. Gazdar, and Michael G. Roth. "Abstract LB-318: SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A-targeted therapies in non-small cell lung cancers (NSCLCs)." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-318.
Повний текст джерелаDu, Liqin, Maria C. Subauste, Michael Baker, Christopher DeSevo, Robert Borkowski, Shihua Zhong, Jeoffrey J. Schageman, et al. "Abstract 4709: miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancers (NSCLCs)." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4709.
Повний текст джерелаTagal, Vural, Shuguang Wei, Wei Zhang, Bruce A. Posner, John D. Minna, Adi F. Gazdar, and Michael G. Roth. "Abstract 573: BRG1-inactivating mutations as potential predictive markers for Aurora kinase A-targeted therapies in non-small cell lung cancers (NSCLCs)." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-573.
Повний текст джерелаYan, Dan, Xiaodong Wang, Stephen V. Frye, Shelton H. Earp, Deborah DeRyckere, and Douglas K. Graham. "Abstract 1082: MerTK promotes resistance to irreversible EGFR TKIs by activation of the PI3K-AKT pathway in NSCLCs expressing wild-type EGFR." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1082.
Повний текст джерелаRauthan, Amit, Poonam Patil, Rajashree Aswath, Nitin Yashas, and Gaurav Ningade. "Immunotherapy in Patients with Lung Cancer with Driver Mutations: A Single-Centre Experience." In Annual Conference of Indian Society of Medical and Paediatric Oncology (ISMPO). Thieme Medical and Scientific Publishers Pvt. Ltd., 2021. http://dx.doi.org/10.1055/s-0041-1735365.
Повний текст джерелаYenerall, Paul M., Rahul Kollipara, Ryan Carstens, Kenneth Huffman, Luc Girard, Jaime Rodriguez, Ignacio Wistuba, David Mangelsdorf, John Minna, and Ralf Kittler. "Abstract 4779: RUVBL1 and RUBVL2 are chromatin remodelers that represent prognostic and novel therapeutic targets for a subset of non-small cell lung cancers (NSCLCs)." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4779.
Повний текст джерелаGreer, Rachel M., Michael Peyton, Luc Girard, Yang Xie, Adi F. Gazdar, Patrick Harran, Lai Wang, Rolf A. Brekken, Xiaodong Wang та John D. Minna. "Abstract 3479: SMAC mimetic (JP1201) sensitizes non small cell lung cancers (NSCLCs) to multiple chemotherapy agents and erlotinib in an IAP dependent but TNFα independent manner". У Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3479.
Повний текст джерелаЗвіти організацій з теми "NSCLCs"
Young, Jamey D., and Young M. Whang. Targeting Redox Homeostasis in LKB1-deficient NSCLC. Fort Belvoir, VA: Defense Technical Information Center, September 2014. http://dx.doi.org/10.21236/ada614534.
Повний текст джерелаPeng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.
Повний текст джерелаWinkles, Jeffrey A. GrB-TWEAK: A Potential Novel Biologic for NSCLC Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2015. http://dx.doi.org/10.21236/ada624531.
Повний текст джерелаFreire, Mariana, Diana Martins, Maria Filomena Botelho, and Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.
Повний текст джерелаOuyang, Zhiqiang, Qian Li, Guangrong Zheng, Tengfei Ke, Jun Yang, and Chengde Liao. Radiomics for predicting tumor microenvironment phenotypes in non-small cell lung cance: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0060.
Повний текст джерелаKudryashov, Dmitri, and Elena Kudryashova. Split and Splice" Approach for Highly Selective Targeting of Human NSCLC Tumors". Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada613862.
Повний текст джерелаKang, Jing, Jun Zhang, Zongsheng Tian, Ye Xu, Jiangbi Li, and Mingxina Li. The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0156.
Повний текст джерелаYendamuri, Saikrishna. Laser Capture Microdissection Assisted Identification of Epithelial MicroRNA Expression Signatures for Prognosis of Stage I NSCLC. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada598453.
Повний текст джерелаYendamuri, Saikrishna. Laser Capture Microdissection Assisted Identification of Epithelial MicroRNA Expression Signatures for Prognosis of Stage I NSCLC. Fort Belvoir, VA: Defense Technical Information Center, October 2011. http://dx.doi.org/10.21236/ada555298.
Повний текст джерелаYendamuri, Sai. Laser Capture Microdissection Assisted Identification of Epithelial MicroRNA Expression Signatures for Prognosis of Stage I NSCLC. Fort Belvoir, VA: Defense Technical Information Center, December 2014. http://dx.doi.org/10.21236/ada621332.
Повний текст джерела